Latest News

HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC
HER2 Amplicon mRNA Signature May Determine Positive Outcomes With T-DXd in mBC

June 2nd 2025

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.
Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer

June 2nd 2025

Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses
Ribociclib Offers Consistent Benefit in HR+ Early Breast Cancer Across All Ages and Menopausal Statuses

June 1st 2025

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.
Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

June 1st 2025

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.
Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

June 1st 2025

More News